CLINICAL TRIALS PROFILE FOR REZUROCK
✉ Email this page to a colleague
All Clinical Trials for REZUROCK
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02841995 ↗ | A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease | Active, not recruiting | Kadmon Corporation, LLC | Phase 2 | 2016-08-01 | This study is being conducted to evaluate the safety, tolerability, and activity of belumosudil (formerly known as KD025) in adult subjects with chronic Graft versus Host Disease (cGVHD). |
| NCT03530995 ↗ | Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers | Completed | Quotient Sciences | Phase 1 | 2018-04-28 | This is a single-center, 2-part, non-randomized, open-label study of the drug-drug interactions of belumosudil (KD025) with itraconazole, rifampicin, rabeprazole, and omeprazole in healthy male subjects. |
| NCT03530995 ↗ | Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers | Completed | Kadmon Corporation, LLC | Phase 1 | 2018-04-28 | This is a single-center, 2-part, non-randomized, open-label study of the drug-drug interactions of belumosudil (KD025) with itraconazole, rifampicin, rabeprazole, and omeprazole in healthy male subjects. |
| NCT03640481 ↗ | Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy | Recruiting | Kadmon Corporation, LLC | Phase 2 | 2018-10-15 | This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of KD025 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least 2 prior lines of systemic therapy |
| NCT05305989 ↗ | Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213 | Enrolling by invitation | Kadmon Corporation, LLC | Phase 2 | 2022-03-01 | Extended Treatment and Follow-up of Subjects Treated with Belumosudil in Study KD025-208 or Study KD025-213 |
| NCT05567406 ↗ | Safety and Efficacy of Oral Belumosudil in Black or African American Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy | Not yet recruiting | Kadmon, a Sanofi Company | Phase 2 | 2022-11-30 | The purpose of this study is to measure safety and efficacy of oral belumosudil in Black or African American male and female participants with cGVHD who have previously been treated with at least 2 prior lines of systemic therapy aged 12 years and above. The duration of subject participation will be up to 4 weeks for screening, treatment until clinically significant progression of disease, and 4 weeks of follow-up i.e., up to approximately 12 months. 1 Cycle = 28 days. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for REZUROCK
Condition Name
Clinical Trial Locations for REZUROCK
Trials by Country
Clinical Trial Progress for REZUROCK
Clinical Trial Phase
Clinical Trial Sponsors for REZUROCK
Sponsor Name
